Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting GOTHENBURG, Sweden and London, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Albireo Limited, a clinical-stage biopharmaceutical company developing through its operating subsidiary novel bile acid modulators to...

Albireo Announces the Initiation in Japan of a Phase 3 Clinical Trial of Elobixibat in Chronic Constipation by Ajinomoto Pharmaceuticals GOTHENBURG, Sweden and LONDON, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Albireo Limited, a clinical-stage biopharmaceutical company developing through its operating subsidiary novel bile acid modulators to...

Albireo Appoints Ron Cooper, Former President of Europe at Bristol-Myers Squibb, as Chief Executive Officer BOSTON, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Albireo Limited, a privately held company focused through its operating subsidiary on the development of bile acid modulators to treat orphan pediatric and...